To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Laureate Announces $9 M Expansion of Manufacturing Facility in Princeton
Laureate Pharma, a partner company of Safeguard Scientifics, have announced plans to invest up to $9 million to expand its biopharmaceutical manufacturing facility in Princeton, NJ.
The facility expansion will provide Laureate Pharma with a pilot production plant with two separate production suites, and expanded purification production capacity to support additional cGMP production.
The pilot plant will include stainless steel stirred tank bioreactors and disposable single use bioreactors - the same technologies used in Laureate’s large-scale, cGMP biomanufacturing facility.
The pilot plant is designed for process development, production and purification of early-phase preclinical proteins and is isolated from Laureate’s main manufacturing area.
Equipments to be installed include bioprocess purification systems, analytical testing systems and associated equipment.
Employment at Laureate is expected to grow by 15% by year-end, in response to increased demand.
Laureate is recruiting additional professional and technical staff to supplement its existing teams. The job postings can be found on the Laureate web site.
"2006 has been a very strong year for Laureate Pharma," said Robert Broeze, PhD, Laureate’s President and CEO.
"In anticipation of continued growth, we are significantly increasing our development and manufacturing capacity to meet our clients’ current and future needs."
"This expansion will enable Laureate Pharma, our partner company, to accommodate increased customer demand for protein-based biopharmaceutical products, without disruption to on-going customer projects," said James Datin, Executive Vice President and Managing Director, Life Sciences of Safeguard Scientifics.
Construction on the expansion has already started, with completion of the pilot production suites targeted for the end of 2006.
The additional cGMP capacity is expected to be operational in mid-2007. Laureate’s primary engineering firm for the project is CE&IC of Burlington, NJ.
